Edition:
United States

Amyris Inc (AMRS.OQ)

AMRS.OQ on NASDAQ Stock Exchange Global Select Market

0.81USD
7 Dec 2016
Change (% chg)

$-0.01 (-0.66%)
Prev Close
$0.81
Open
$0.82
Day's High
$0.82
Day's Low
$0.80
Volume
126,931
Avg. Vol
851,900
52-wk High
$1.81
52-wk Low
$0.31

AMRS.OQ

Chart for AMRS.OQ

About

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including... (more)

Overall

Beta: 0.39
Market Cap(Mil.): $213.67
Shares Outstanding(Mil.): 263.02
Dividend: --
Yield (%): --

Financials

  AMRS.OQ Industry Sector
P/E (TTM): -- 15.56 16.68
EPS (TTM): -0.42 -- --
ROI: -398.76 7.62 8.74
ROE: -- 9.42 10.66

BRIEF-Amyris achieves key milestone in major drug discovery collaboration

* Amyris achieves key milestone in major drug discovery collaboration Source text for Eikon: Further company coverage:

Nov 16 2016

BRIEF-Amyris reports Q3 loss per share $0.08

* Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Nov 02 2016

BRIEF-Amyris executes definitive agreements for strategic partnership, financing

* Amyris executes definitive collaboration agreements with leading global nutraceuticals partner

Oct 26 2016

BRIEF-Amyris agrees to collaborate with leading global food ingredients and nutraceuticals partner

* Amyris agrees to collaboration terms with leading global food ingredients and nutraceuticals partner

Oct 13 2016

BRIEF-Amyris expanded its strategic partnership with a "global nutraceuticals market leader"

* Expanded its strategic partnership with a "global nutraceuticals market leader"

Sep 30 2016

BRIEF-Amyris & Ginkgo Bioworks complete collaboration agreement to accelerate commercialization of bio-based products

* Amyris & Ginkgo Bioworks complete collaboration agreement to accelerate commercialization of bio-based products

Sep 15 2016

BRIEF-Amyris Q2 adjusted loss per share $0.15

* Q2 2016 GAAP revenues of $9.6 million (non-GAAP revenues of $12.4 million)

Aug 04 2016

BRIEF-Amyris enters partnership with Biogen

* Collaboration will explore use of Amyris's microbe engineering technology

Aug 03 2016

BRIEF-American Refining Group invests in Novvi to accelerate Amyris commercialization of renewable base oil and lubricant platform

* American Refining Group invests in Novvi to accelerate Amyris commercialization of renewable base oil and lubricant platform

Jul 19 2016

BRIEF-Amyris entered into note purchase agreement with Foris Ventures LLC

* On June 24, 2016 entered into note purchase agreement with Foris Ventures LLC for sale of $5 million in aggregate principal amount of secured promissory notes

Jun 29 2016

Earnings vs. Estimates